Guidance PacBio has lowered its financial outlook for full-year 2022 due to broader macroeconomic factors like rising inflation, global supply-chain constraints, volatile capital markets and COVID-19-led lockdown restrictions. Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered adjusted loss per share of 34 cents in the second quarter of 2022, wider than the year-ago loss of 21 cents per share. Revenues in Detail PacBio registered revenues of $35.5 million in the second quarter, up 15.9% year over year.